BioMAX is the first X-ray macromolecular crystallography beamline of MAX IV Laboratory, which is in user operations since 2017. It is a state-of-the-art resource accommodating multiple cutting edge experimental possibilities. The design goal for BioMAX was to create a stable and reliable beamline that is user friendly. The beamline experiment set-up is highly automated, in terms of both sample handling hardware and data analysis, including feedback on the data collection.

The X-ray beam focus is 20 x 5 μm2 at the sample position with a photon flux of 2 x 1013 ph/s at 500 mA ring current. The operational energy range of the beamline is 5–25 keV. Alternatively, using aperture overfilling it is possible to obtain a stable 5 x 5 μm2 beam at the sample position. Due to its extensive energy tunability, BioMAX is an ideal source for de novo phasing using the anomalous signal of heavy elements. Beam defocusing creates a practically parallel beam, which can be used to resolve extremely large unit cells > 1000 Å at high resolution. Due to its small beam cross-section and optional parallel beam, BioMAX is an optimal experimental set-up for X-ray crystallography using microcrystals and ultra large unit cells. Initial synchrotron based serial crystallography (SSX) experiments using an High-Viscosity-Extrusion injector designed and built by Bruce Doak (MPI-Heidelberg) have been carried out.

Techniques

Available forTechnique description
General UsersData collection at fixed energy between 6 and 19.5 keV, detector distance between 126 and 900 mm, beam focus of 20x5 microns or 50x50 microns and defining aperture of 5, 10, 20 or 50 microns
General UsersAutomated sample mounting and dismounting from UniPucks, 29 puck positions in dewar
General UsersSample temperature 100 K; room temperature with or without humidity control available for manual mounting only
General UsersSAD and MAD experiments
General UsersAutomated data integration, scaling and merging. Offline remote access for manual data processsing.
General UsersSX experiments using HVE-injector (High viscosity extrusion injector), fixed target scan using the MD3
General UsersElement identification by X-ray Fluorescence
General UsersRemote data collection. Under development. Please contact beamline manager
General UsersFragment-based drug screening. Under development. Please contact beamline manager
See also BioMAX User Information

2020-07-01

First Test of FragMAX Platform Delivers for HZB Compound Libraries

image: User interface for FragMAX screening platform at MAX IV Researchers at Helmholtz-Zentrum Berlin (HZB), in collaboration with MAX IV’s BioMAX team, have validated a new diverse universal compound library used in the process of drug discovery and development. The HZB study, published in CellPress, sourced the power of MAX IV’s macromolecular crystallography beamline BioMAX

FragMAX platform interface